Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children
|Komal Sodhi1*, Lucas Bracero2, Andrew Feyh2, Alexandra Nichols2, Krithika Srikanthan2, Tariq Latif2, Deborah Preston3, Joseph I Shapiro1 and Yoram Elitsur3|
|1Department of Surgery and Pharmacology, Joan C. Edwards School of Medicine, Marshall University, USA|
|2Department of Internal Medicine, Joan C. Edwards School of Medicine, Marshall University, USA|
|3Department of Pediatrics, Division of Gastroenterology, Joan C. Edwards School of Medicine, Marshall University, USA|
|Corresponding Author :||Komal Sodhi
M.D., Assistant Professor of Surgery and
Pharmacology, Joan C Edwards School of Medicine
Marshall University, WV 25701, USA
Fax: 914 347-4956
E-mail: [email protected]
|Received: December 28, 2015 Accepted: February 08, 2016 Published: February 17, 2016|
|Citation: Sodhi K, Bracero L, Feyh A, Nichols A, Srikanthan K, et al. (2016) Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children. J Clin Cell Immunol 7:393. doi:10.4172/2155-9899.1000393|
|Copyright: © 2016 Sodhi K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
Background: Obesity, an epidemic among West Virginia children, as well as insulin resistance (IR), is wellestablished contributors to nonalcoholic steatohepatitis (NASH). Progression of NASH can lead to hepatic fibrosis and cirrhosis, making early detection imperative. The standard for diagnosing NASH is histologically via liver biopsy, which is highly invasive and generally contraindicated in children. By studying serum biomarkers associated with NASH, we aim to identify high risk children who can benefit from a less invasive, alternative approach to the early detection of NASH.
Methods: Seventy one children were prospectively recruited and divided into 3 groups: normal weight without IR (control), obese without IR, and obese with IR. Serum samples were drawn for each patient and biomarker levels were assessed via ELISA kits.
Results: Obese without IR and obese with IR patients had significantly elevated levels of lipid metabolism and accumulation markers (FGF-21, NEFA, FATP5, ApoB), oxidative stress markers (dysfunctional HDL, 8-Isoprostane), inflammatory markers(dysfunctional HDL, CK-18) and apoptosis markers (CK-18) compared to control patients (p<0.02). Bilirubin (an antioxidant) was significantly decreased in the obese without IR and obese with IR patients compared to control (p<0.02).
Conclusion: This study showed a correlation between obesity, IR, and biomarkers associated with NASH in pediatrics patients from West Virginia, with obese with IR patients showing the strongest correlation. These findings support the clinical application of these serum biomarkers as a less invasive method for early detection of NASH and hepatic fibrosis.